OxidoResist

Identification and validation of complementary therapies to
overcome resistance to a novel anticancer compound inducing
oxidative stress in cancer cells.

 

Europa

EUREKA

 

 

 

 

As a Eurostars project, OxidoResist is an international, SME-driven project for innovative product development with a fast track to market.

The OxidoResist project aims to develop a technology to overcome anticancer drug resistance. The OxidoResist technology will apply innovative single cell proteomics and modern AI-based bioinformatics to identify FDA-approved drug(s) that will overcome resistance and have a synergistic effect in combination with a given anti-cancer drug.
We will develop a universal pipeline (joining wet lab, AI-based bioinformatics, cheminformatics and network modeling approaches) for the discovery of optimal complementary drug combinations to fight the resistance to target-specific therapeutic agents. The developed pipeline will be applied to a new highly effective target-specific anticancer compound that was developed in the EuroStars project OxidoCurin (2017-2020).

Further information

The OxidoResist project aims to develop a technology to overcome drug resistance in cancer. The OxidoResist technology will apply the innovative single-cell proteomics and modern AI-based bioinformatics to discover which FDA-approved drugs will overcome resistance when combined with the anticancer drug under study. We will develop a universal pipeline for the discovery of optimal drug combinations that overcome resistance to target-specific therapies.

The project aims to develop and introduce two new products on the market:

1) Medicines against cancer with a new mechanism of action

2) Service platform

The project aims to develop a technology to overcome anticancer drug resistance. The technology will apply the innovative single cell proteomics and modern AI-based bioinformatics to discover which FDA-approved drugs will overcome resistance in combination with anti-cancer drugs under study. We will develop a universal pipeline (joining top labs, AI-based bioinformatics, chemoinformatics, and network modeling) for the discovery of optimal drug combinations that overcome resistance to target-specific therapies.

Contract period

January 2023 – December 2024

Coordinator

The project is coordinated by Dr. Alexander Kel, geneXplain GmbH, Wolfenbüttel, Germany

Partners

×